Salvinorin A Inhibits Airway Hyperreactivity Induced by Ovalbumin Sensitization
Overview
Authors
Affiliations
Salvinorin A, a neoclerodane diterpene isolated from , exerts a number of pharmacological actions which are not solely limited to the central nervous system. Recently it has been demonstrated that Salvinorin A inhibits acute inflammatory response affecting leukotriene (LT) production. Since LTs are potent lipid mediators implicated in allergic diseases, we evaluated the effect of Salvinorin A on allergic inflammation and on airways following sensitization in the mouse. Mice were sensitized with s.c. injection of ovalbumin (OVA) on days 1 and 8. Sensitized mice received on days 9 and 12 on the shaved dorsal surface air administration to induce the development of the air-pouches. On day 15 animals were challenged by injection of OVA into the air-pouch. Salvinorin A, administered (10 mg/kg) before each allergen exposure, significantly reduced OVA-induced LT increase in the air pouch. This effect was coupled to a reduction in cell recruitment and Th2 cytokine production. In another set of experiments, mice were sensitized with OVA and both bronchial reactivity and pulmonary inflammation were assessed. Salvinorin A abrogated bronchial hyperreactivity and interleukin (IL)-13 production, without effect on pulmonary inflammation. Indeed cell infiltration and peribronchial edema were still present following diterpenoid treatment. Similarly, pulmonary IL-4 and plasmatic IgE levels were not modulated. Conversely, Salvinorin A significantly reduced LTC production in the lung of sensitized mice. Finally mast cell activity was evaluated by means of toluidine blue staining. Data obtained evidenced that Salvinorin A significantly inhibited mast cell degranulation in the lung. Our study demonstrates that Salvinorin A inhibits airway hyperreactivity induced by sensitization by inhibition of LT production and mast cell degranulation. In conclusion Salvinorin A could represent a promising candidate for drug development in allergic diseases such as asthma.
DAvino D, Cerqua I, Ullah H, Spinelli M, Di Matteo R, Granato E Int J Mol Sci. 2023; 24(13).
PMID: 37446131 PMC: 10342042. DOI: 10.3390/ijms241310954.
Ren Y, Zhang H, Yu Z, Yang X, Jiang D Comb Chem High Throughput Screen. 2023; 27(2):227-237.
PMID: 37138477 DOI: 10.2174/1386207326666230503112343.
CD73: Friend or Foe in Lung Injury.
Hu X, Shi N, Zhang J, Zuo Y, Wang X, Zhao Y Int J Mol Sci. 2023; 24(6).
PMID: 36982618 PMC: 10056814. DOI: 10.3390/ijms24065545.
Cerqua I, Musella S, Peltner L, DAvino D, Di Sarno V, Granato E J Med Chem. 2022; 65(21):14456-14480.
PMID: 36318728 PMC: 9661480. DOI: 10.1021/acs.jmedchem.2c00817.
Hu X, Hong B, Sun M Evid Based Complement Alternat Med. 2022; 2022:2090478.
PMID: 35990849 PMC: 9391104. DOI: 10.1155/2022/2090478.